Quantitative HRAMS Assay for GLP-1 Analogues
Obesity, Type 2 Diabetes, Cardiometabolic Disease (Supporting Clinical Trials)
Service PlatformActive
Key Facts
Indication
Obesity, Type 2 Diabetes, Cardiometabolic Disease (Supporting Clinical Trials)
Phase
Service Platform
Status
Active
Company
About PeploBio
PeploBio operates as a hybrid diagnostics and CRO services company, leveraging high-resolution mass spectrometry (HRAMS) and immunoassay platforms to support pharmaceutical clinical development, particularly in metabolic disease. Its flagship offering is a quantitative HRAMS assay for GLP-1 receptor agonists, developed in partnership with Kingston Analytical Services Toxicology (KAST), enabling precise drug level measurement in clinical trials. The company's model combines laboratory testing, assay development/validation, and biospecimen sourcing to serve the growing precision medicine and clinical research markets.
View full company profile